BRPI0720251B8 - derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo - Google Patents
derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmoInfo
- Publication number
- BRPI0720251B8 BRPI0720251B8 BRPI0720251A BRPI0720251A BRPI0720251B8 BR PI0720251 B8 BRPI0720251 B8 BR PI0720251B8 BR PI0720251 A BRPI0720251 A BR PI0720251A BR PI0720251 A BRPI0720251 A BR PI0720251A BR PI0720251 B8 BRPI0720251 B8 BR PI0720251B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- compound
- combination
- product
- pharmaceutical composition
- Prior art date
Links
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 8
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06125521 | 2006-12-06 | ||
| EP06125521.2 | 2006-12-06 | ||
| PCT/EP2007/063315 WO2008068269A1 (en) | 2006-12-06 | 2007-12-04 | Antibacterial quinoline derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0720251A2 BRPI0720251A2 (pt) | 2014-01-07 |
| BRPI0720251B1 BRPI0720251B1 (pt) | 2020-10-06 |
| BRPI0720251B8 true BRPI0720251B8 (pt) | 2021-05-25 |
Family
ID=37944337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0720251A BRPI0720251B8 (pt) | 2006-12-06 | 2007-12-04 | derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7998979B2 (enExample) |
| EP (1) | EP2086941B1 (enExample) |
| JP (1) | JP5356245B2 (enExample) |
| KR (1) | KR101490221B1 (enExample) |
| CN (1) | CN101541752B (enExample) |
| AR (1) | AR064150A1 (enExample) |
| AT (1) | ATE465994T1 (enExample) |
| AU (1) | AU2007328889B2 (enExample) |
| BR (1) | BRPI0720251B8 (enExample) |
| CA (1) | CA2668520C (enExample) |
| CL (1) | CL2007003516A1 (enExample) |
| CY (1) | CY1110706T1 (enExample) |
| DE (1) | DE602007006231D1 (enExample) |
| DK (1) | DK2086941T3 (enExample) |
| ES (1) | ES2344535T3 (enExample) |
| HR (1) | HRP20100384T1 (enExample) |
| IL (1) | IL199081A (enExample) |
| JO (1) | JO2685B1 (enExample) |
| ME (1) | ME01073B (enExample) |
| MX (1) | MX2009005980A (enExample) |
| NO (1) | NO341995B1 (enExample) |
| NZ (1) | NZ576673A (enExample) |
| PL (1) | PL2086941T3 (enExample) |
| PT (1) | PT2086941E (enExample) |
| RS (1) | RS51390B (enExample) |
| RU (1) | RU2446159C2 (enExample) |
| SI (1) | SI2086941T1 (enExample) |
| TW (1) | TWI412364B (enExample) |
| WO (1) | WO2008068269A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104254527B (zh) | 2012-04-27 | 2017-05-31 | 詹森药业有限公司 | 抗菌的喹啉衍生物 |
| AU2013254670B2 (en) | 2012-04-27 | 2017-03-30 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| CN104650054B (zh) * | 2013-11-25 | 2019-09-13 | 重庆医药工业研究院有限责任公司 | 一种抗结核菌的喹啉噻吩芳氧乙胺衍生物 |
| WO2018048882A1 (en) | 2016-09-06 | 2018-03-15 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
| JP2025510646A (ja) | 2022-03-14 | 2025-04-15 | スラップ ファーマシューティカルズ エルエルシー | 多環式化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6033389B2 (ja) * | 1979-02-22 | 1985-08-02 | 日産化学工業株式会社 | 複素環エ−テル系フェノシキ脂肪酸誘導体、その製造法および該誘導体を含有する除草剤 |
| WO1998018326A1 (en) | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
| KR20040055774A (ko) * | 2001-07-31 | 2004-06-26 | 웨인 스테이트 유니버시티 | 퀴놀린 유도체 및 항종양제로서 그의 용도 |
| DK2301544T3 (da) * | 2002-07-25 | 2013-01-02 | Janssen Pharmaceutica Nv | Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer |
| WO2005070430A1 (en) * | 2004-01-23 | 2005-08-04 | Janssen Pharmaceutica N.V. | Quinoline derivatives and use thereof as mycobacterial inhibitors |
| WO2005070924A1 (en) | 2004-01-23 | 2005-08-04 | Janssen Pharmaceutica N.V. | Substituted quinolines and their use as mycobacterial inhibitors |
| ES2306098T3 (es) * | 2004-01-29 | 2008-11-01 | Janssen Pharmaceutica Nv | Derivados de quinolina para uso como inhibidores de micobacterias. |
| EP1753427B1 (en) * | 2004-05-28 | 2008-04-02 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
| ME02935B (me) | 2004-09-28 | 2018-04-20 | Janssen Pharmaceutica Nv | Vezujući domen bakterijske atp sintaze |
-
2007
- 2007-11-29 JO JO2007507A patent/JO2685B1/en active
- 2007-12-04 RU RU2009125525/04A patent/RU2446159C2/ru active
- 2007-12-04 JP JP2009539740A patent/JP5356245B2/ja not_active Expired - Fee Related
- 2007-12-04 KR KR1020097012572A patent/KR101490221B1/ko not_active Expired - Fee Related
- 2007-12-04 AT AT07847813T patent/ATE465994T1/de active
- 2007-12-04 PT PT07847813T patent/PT2086941E/pt unknown
- 2007-12-04 DE DE602007006231T patent/DE602007006231D1/de active Active
- 2007-12-04 HR HR20100384T patent/HRP20100384T1/hr unknown
- 2007-12-04 AU AU2007328889A patent/AU2007328889B2/en not_active Ceased
- 2007-12-04 EP EP07847813A patent/EP2086941B1/en active Active
- 2007-12-04 SI SI200730286T patent/SI2086941T1/sl unknown
- 2007-12-04 CA CA2668520A patent/CA2668520C/en active Active
- 2007-12-04 US US12/516,370 patent/US7998979B2/en active Active
- 2007-12-04 PL PL07847813T patent/PL2086941T3/pl unknown
- 2007-12-04 CN CN2007800437666A patent/CN101541752B/zh not_active Expired - Fee Related
- 2007-12-04 ES ES07847813T patent/ES2344535T3/es active Active
- 2007-12-04 DK DK07847813.8T patent/DK2086941T3/da active
- 2007-12-04 NZ NZ576673A patent/NZ576673A/en not_active IP Right Cessation
- 2007-12-04 ME MEP-2010-111A patent/ME01073B/me unknown
- 2007-12-04 RS RSP-2010/0340A patent/RS51390B/sr unknown
- 2007-12-04 BR BRPI0720251A patent/BRPI0720251B8/pt not_active IP Right Cessation
- 2007-12-04 MX MX2009005980A patent/MX2009005980A/es active IP Right Grant
- 2007-12-04 WO PCT/EP2007/063315 patent/WO2008068269A1/en not_active Ceased
- 2007-12-05 TW TW096146213A patent/TWI412364B/zh not_active IP Right Cessation
- 2007-12-05 CL CL200703516A patent/CL2007003516A1/es unknown
- 2007-12-05 AR ARP070105443A patent/AR064150A1/es unknown
-
2009
- 2009-06-02 IL IL199081A patent/IL199081A/en active IP Right Grant
- 2009-07-06 NO NO20092540A patent/NO341995B1/no unknown
-
2010
- 2010-07-28 CY CY20101100708T patent/CY1110706T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0720220B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo | |
| BRPI0719920B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário | |
| BRPI0610850A2 (pt) | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados | |
| BRPI0510414A (pt) | uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos | |
| BRPI0821115A8 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
| ATE517882T1 (de) | Chinolinderivate | |
| BR122019010200B8 (pt) | compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas | |
| BR112014003063A2 (pt) | "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com ciclopenta[c]pirrol antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso". | |
| ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
| BR112014002958A2 (pt) | "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com piperidinila antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso". | |
| BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
| BRPI0720251B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo | |
| MX2014013056A (es) | Derivados de quinolina antibacterianos. | |
| CY1112230T1 (el) | Αντιβακτηριακα παραγωγα κινολινης | |
| BRPI0719939B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo | |
| BRPI0614122A8 (pt) | composto derivado de quinolina, composição farmacêutica e uso do referido composto | |
| CY1112027T1 (el) | Αντιβακτηριακα παραγωγα κινολινης | |
| BRPI0613999B8 (pt) | uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto | |
| BRPI0612534B8 (pt) | uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto | |
| BR112023017040A2 (pt) | Derivados de indolina como inibidores de ddr1 e ddr2 | |
| BR112023002077A2 (pt) | Composto e seu uso, composição e formulação farmacêutica | |
| BR112014026776A2 (pt) | derivados de pirimidina para o tratamento de doenças bacterianas | |
| EA200970570A1 (ru) | Макролидные соединения, обладающие противовоспалительной активностью |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2804 DE 01-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |